Back in January, we told you about a different kind of COVID vaccine that had just been approved for use in India. The vaccine, called Corbevax, had some very attractive properties: It's low-cost, easy to make using well-established biotech processes — and patent-free.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
